EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

Khê Hoang-Xuan, Martina Deckert, Andrés J M Ferreri, Julia Furtner, Jaime Gallego Perez-Larraya, Roger Henriksson, Andreas F Hottinger, Benjamin Kasenda, Florence Lefranc, Alexander Lossos, Catherine McBain, Matthias Preusser iD und 9 weitere

Neuro-Oncology · 05.01.2023 · 25 (1) · 37-53

DOI: 10.1093/neuonc/noac196 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Neuro-Oncology, online erschienen am 12.08.2022. Verfasst von Khê Hoang-Xuan und 20 weiteren Autor:innen. Beteiligte Einrichtung: APHP, Department of Neurology, Groupe Hospitalier Pitié-Salpêtrière; Sorbonne Université; IHU; ICM. Paris, France. Hauptthemen laut MEDLINE: Central Nervous System Neoplasms, Lymphoma. Die Arbeit wurde bisher 170-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and the publication of practice-changing randomized trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The guideline provides consensus considerations and recommendations for the treatment of PCNSL, including intraocular manifestations and specific management of the elderly. The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System NeoplasmsLymphomaAdultHumansAgedCombined Modality TherapyAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous System

Stichwörter der Autor:innen

chemotherapyimmunotherapyprimary CNS lymphomaradiotherapytreatment

Autor:innen und Institutionen

  • APHP, Department of Neurology, Groupe Hospitalier Pitié-Salpêtrière; Sorbonne Université; IHU; ICM. Paris, France.
  • Institute of Neuropathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.
  • Department of Biomedical and Imaging Image-guided Therapy Medical University of Vienna, Vienna, Austria.
  • Health Research Institute of Navarra (IdiSNA), Program in Solid Tumors, Foundation for the Applied Medical Research, Department of Neurology, Clinica Universidad de Navarra, Pamplona, Navarra, Spain.
  • Department of Radiation Sciences, Oncology, University of Umeå, S-901 85 Umea, Sweden.

ORCID-Profile: Matthias Preusser, Riccardo Soffietti, Michael Weller

Zitieren

APA

Hoang-Xuan, K., Deckert, M., Ferreri, A. J. M., Furtner, J., Gallego Perez-Larraya, J., Henriksson, R., Hottinger, A. F., Kasenda, B., Lefranc, F., Lossos, A., McBain, C., Preusser, M., Roth, P., Rudà, R., Schlegel, U., Soffietti, R., Soussain, C., Taphoorn, M. J. B., Touitou, V., …, & Bromberg, J. E. C. (2023). European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro-Oncology, 25(1), 37-53. https://doi.org/10.1093/neuonc/noac196

Vancouver

Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, et al. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro-Oncology. 2023;25(1):37-53. doi:10.1093/neuonc/noac196

BibTeX
@article{HoangXuan2023,
  author = {Hoang-Xuan, Khê and Deckert, Martina and Ferreri, Andrés J M and Furtner, Julia and Gallego Perez-Larraya, Jaime and Henriksson, Roger and Hottinger, Andreas F and Kasenda, Benjamin and Lefranc, Florence and Lossos, Alexander and McBain, Catherine and Preusser, Matthias and Roth, Patrick and Rudà, Roberta and Schlegel, Uwe and Soffietti, Riccardo and Soussain, Carole and Taphoorn, Martin J B and Touitou, Valérie and Weller, Michael and Bromberg, Jacoline E C},
  title = {European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)},
  journal = {Neuro-Oncology},
  year = {2023},
  volume = {25},
  number = {1},
  pages = {37--53},
  doi = {10.1093/neuonc/noac196}
}
Kostenlos starten →